Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock. Hunterbrook said on Thursday that it has a short position on DXCM ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

Earlier on November 25, Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. While ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device ...

San Diego-based Dexcom, a maker of continuous glucose monitors, has filed for a patent for a system that would integrate a smartphone with a Dexcom device, detailing some of the features such a device ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...